Importantly, blocking the transcription factor responsible for the Th17 response (e.g., RORγt) transforms the TME by depleting IL17 within the tumor which subsequently leads to a significant decrease in the prophylactic efficacy of the dendritic cell (DC) vaccine (114). The gene discussed is IL17A; the disease is neoplasm.